Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib Switch for Imatinib-Related Adverse Events in CML-CP
NCT00980018Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2009
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 4 trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Novartis. Started Dec 2009; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00980018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00980018.